Levetiracetam

CHEMBL1286 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

170.2 g/mol

LogP

-0.3

Phase

4

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Молекулярная масса

170,2100 g/mol

LogP

-0,30

TPSA

63,40 Å²

Правило пяти Липинского

Соответствует

Терапевтические области

Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Multiple Sclerosis Stroke Lymphoma Chronic Pain Malaria Leukemia

Механизм действия

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@@H](C(N)=O)N1CCCC1=O

InChI

InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

Molecular Formula

C8H14N2O2

HBD / HBA

1 / 2

Вращаемые Связи

3

Тяжёлые Атомы

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Levetiracetam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1286. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5284583. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Ищете информацию, доступную для пациентов?

Levetiracetam на PillFYI

Структура

Краткие Данные

Формула: C8H14N2O2
Синонимы: 10

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.